Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.49 |
| ▸ | DPP4 | P27487 | 5/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | FAP | Q12884 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | MC5R | P33032 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27800005 | 1.00 | OPRD1 (0.49) | OPRD1DPP4DPP8DPP9DPP7 | |
| SCHEMBL3361699 | 0.87 | CYP51A1 (0.46) | OPRD1CYP51A1POLBHRH2HRH1 | |
| SCHEMBL868066 | 0.82 | GHSR (0.42) | OPRD1DPP4DPP8DPP9DPP7 | |
| SCHEMBL868065 | 0.82 | GHSR (0.42) | OPRD1DPP4DPP8DPP9DPP7 | |
| SCHEMBL868545 | 0.81 | GHSR (0.57) | OPRD1DPP4CYP51A1 | |
| SCHEMBL868544 | 0.81 | GHSR (0.57) | OPRD1DPP4CYP51A1 | |
| SCHEMBL867707 | 0.79 | GHSR (0.40) | OPRD1DPP4DPP8DPP9DPP7 | |
| SCHEMBL15533171 | 0.79 | GHSR (0.40) | OPRD1DPP4DPP8DPP9DPP7 | |
| SCHEMBL867706 | 0.79 | GHSR (0.40) | OPRD1DPP4DPP8DPP9DPP7 | |
| SCHEMBL3133533 | 0.78 | OPRD1 (0.65) | OPRD1DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576062-B2 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | NOVO NORDISK A/S (DK) | 2009-08-18 | — | — | US | claimed |
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | HELSINN HEALTHCARE SA (CH) | 2005-10-20 | — | — | US | claimed |
| US-6919315-B1 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-07-19 | — | — | US | claimed |
| EP-1100824-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2001-05-23 | — | — | EP | claimed |
| WO-2000001726-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2000-01-13 | — | — | WO | claimed |
| US-8394833-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8288427-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-1789067-B8 | Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system | HELSINN HEALTHCARE SA (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20100087381-A1 | Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2010-04-08 | — | — | US | disclosed |
| EP-2146732-A1 | METHODS OF TREATING OR PREVENTING EMESIS USING GROWTH HORMONE SECRETAGOGUES | Helsinn Therapeutics (U.S.), Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2134341-A2 | METHOD OF TREATING CELL PROLIFERATIVE DISORDERS USING GROWTH HORMONE SECRETAGOGUES | Helsinn Therapeutics (U.S.), Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | REJUVENON CORPORATION | 2007-08-16 | — | — | US | disclosed |
| EP-1789067-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | Sapphire Therapeutics, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006020930-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | SAPPHIRE THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20050261201-A1 | Method of reducing C-reactive protein using growth hormone secretagogues | REJUVENON CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | HELSINN HEALTHCARE SA (CH) | 2005-10-20 | — | — | US | disclosed |
| US-6919315-B1 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-07-19 | — | — | US | disclosed |
| EP-1100824-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000001726-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261201-A1 | Method of reducing C-reactive protein using growth hormone secretagogues | CETP, FABP7, TGFB1 | OPRD1 3955/4885DPP4 436/4885DPP8 488/4885 |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | GHSR, GHRHR, CRH | OPRD1 3939/4885DPP4 216/4885DPP8 189/4885 |
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | GHSR, GHRHR, MC2R | OPRD1 681/4885DPP4 2216/4885DPP8 2388/4885 |
| US-20100087381-A1 | Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues | GHSR, GHRHR, MLNR | OPRD1 57/4885DPP4 153/4885DPP8 376/4885 |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | GHSR, GHRHR, MLNR | OPRD1 57/4885DPP4 153/4885DPP8 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.